Table 2.
Comparison of long-term follow-up physical examinations outcomes between 2 study groups.
| Characteristic | Control group | LP + IVR group | p value |
|---|---|---|---|
| BW at birth, g, mean (SD) | 1553.5 (392.7) | 831.4 (140.9) | 0.001a∗ |
| GA at birth, week, mean (SD) | 29.8 (1.4) | 27.5 (1.7) | 0.001a∗ |
| Chronological age at physical examination, months, mean (SD) | 29.8 (6.0) | 30.0 (9.6) | 0.797a |
| Ophthalmic outcomes | |||
| BCVA, log MAR, mean (SD) | 0.3 (0.1) | 0.4 (0.1) | 0.172a |
| SE, D, mean (SD) | +2.1 (0.6) | +1.9 (0.7) | 0.086a |
| AL, mm, mean (SD) | 21.6 (0.6) | 21.9 (0.7) | 0.140a |
| Somatic outcomes | |||
| BW, kg, mean (SD) | 15.1 (1.4) | 14.8 (1.6) | 0.608a |
| Body height, cm, mean (SD) | 95.5 (5.4) | 94.9 (4.3) | 0.737a |
| Head circumference, cm, mean (SD) | 48.2 (0.9) | 47.9 (0.7) | 0.279a |
| Developmental outcome (GDDS), M (P25, P75), range | |||
| Gross motor | 91 (85, 95) 77 to 100 |
89 (80, 93) 67 to 99 |
0.166b |
| Fine motor | 92 (86, 95) 75 to 99 |
87 (84, 93) 69 to 99 |
0.154b |
| Adaptability | 93 (88, 95) 76 to 99 |
88 (81, 94) 66 to 100 |
0.137b |
| Language | 89 (84, 94) 67 to 99 |
87 (84, 92) 70 to 99 |
0.278b |
| Personal-social | 91 (85, 96) 76 to 98 |
90 (84, 94) 77 to 98 |
0.391b |
Note: IVR, intravitreal injection of ranibizumab.
Abbreviations: BW, body weight; CCH, cumulative clock hours; GA, gestational age; LP, laser photocoagulation; PMA, postmenstrual age; ROP, retinopathy of prematurity; SD, standard deviation.
aindependent t-test.
bWilcoxon rank-sum test.
∗ p < 0.05.